Nanobac Life Sciences Announces Publication of Results in the Journal of Urology Demonstrating Significant Improvement in Symptoms of Prostatitis Using comET Therapy.

TAMPA, Fla. -- Nanobac Life Science, Inc. (OTCBB:NNBP), announced today results of a study providing evidence that its patented combination of EDTA, tetracycline and a proprietary blend of nutritional supplements (comET Therapy) demonstrated significant improvement in symptoms in a group of patients with prostatitis or Chronic Pelvic Pain Syndrome (CPPS). The observational study, lead by Daniel A. Shoskes, M.D., of Cleveland Clinic Florida, demonstrated a significant decrease in the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) score in patients with recalcitrant prostatitis who took 3 months of Nanobac's proprietary comET nanobiotic regimen. The results of the study currently appear online and will appear in the print version of the Journal of Urology, Vol. 173, February 2005.

The treated group of fifteen patients had prostatic stones and longstanding Chronic Pelvic Pain Syndrome (CPPS) symptoms unresponsive to multiple prior conventional therapies. The treatment is designed to eliminate stone forming Nanobacteria. The study found 80% of the patients had a significant improvement in symptoms after 3 months of the comET regimen. Two patients who had been on complete medical disability have returned to work.

"The study population represented a truly 'hard core' group of patients who had failed multiple previous therapies including antibiotics, phytotherapy, alpha blockers, neuromuscular therapies and prostatic massage," said Daniel Shoskes, MD, study principal investigator. "A response of such magnitude, even in an uncontrolled study is noteworthy in this patient population."

Patients were also evaluated for nanobacterial antigen and antibody positivity. Nine men (60%) had nanobacterial antigen or antibody detected in the blood, six (40%) had nanobacterial antigen in the urine.

About CPPS/Prostatitis

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) suggests that Prostatitis might account for up to 25 percent of all office visits by young and middle-aged men for complaints involving the genital and urinary systems. The term prostatitis actually encompasses four disorders: Acute bacterial prostatitis, Chronic bacterial prostatitis, Chronic prostatitis/chronic pelvic pain syndrome (CPPS) and Asymptomatic inflammatory prostatitis. CPPS is the most common but least understood form of prostatitis. It is found in men of any age and its symptoms have a profound effect on quality of life. Symptoms include pain (pelvic and genitals), urinary frequency and erectile dysfunction.

About Nanobac Life Sciences

Nanobac Life Sciences, Inc. is dedicated to improving people's health through the detection and eradication of Nanobacterium sanguineum (Nanobacteria). The Company's pioneering research is establishing the pathogenic role of Nanobacteria in calcification, particularly in coronary artery heart disease and vascular disease. Nanobac has identified two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2(TM) ELISA assays to detect nanobacterial antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop the first FDA approved therapeutic to treat nanobacterial infection. The Company currently markets a patented nanobiotic regimen. For further information concerning our nanobiotic, please visit http://www.nanobacsciences.com.

Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobaclifesciences.com.

Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.